Analysis confirms benefit of nivolumab combo in teens with advanced Hodgkin lymphoma

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin (brand name Adcetris) along with chemotherapy,…

Continue Reading

News Source: medicalxpress.com